Adjuvant chemotherapy in primary treatment of osteogenic sarcoma. A Southwest Oncology Group study
- PMID: 1059501
- DOI: 10.1002/1097-0142(197511)36:5<1598::aid-cncr2820360511>3.0.co;2-n
Adjuvant chemotherapy in primary treatment of osteogenic sarcoma. A Southwest Oncology Group study
Abstract
A four-drug adjuvant chemotherapy regimen (CONPADRI-I) was utilized in the primary treatment of 18 children with osteogenic sarcoma. All patients had surgical amputation for the primary lesion. The children then received cyclophosphamide, vincristine, melphalan, and adriamycin in defined combinations intermittently over a 72-week period. Of the 18 patients, 10 (55%) remain free of disease 24 months or longer from time of amputation.